{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:25:24Z","timestamp":1781306724000,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-026-04156-6","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T03:43:15Z","timestamp":1770608595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beta-blockers improve neurological outcomes of cerebral cavernous malformations: a systematic review"],"prefix":"10.1007","volume":"49","author":[{"given":"Yufang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"4156_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrneurol.2009.177","volume":"5","author":"S Batra","year":"2009","unstructured":"Batra S, Lin D, Recinos PF, Zhang J, Rigamonti D (2009) Cavernous malformations: natural history, diagnosis and treatment. Nat Rev Neurol 5:659\u2013670. https:\/\/doi.org\/10.1038\/nrneurol.2009.177","journal-title":"Nat Rev Neurol"},{"key":"4156_CR2","first-page":"199","volume":"59","author":"M Fontanella","year":"2015","unstructured":"Fontanella M, Bacigaluppi S (2015) Treatment of cerebral cavernous malformations: where do we stand? J Neurosurg Sci 59:199\u2013200","journal-title":"J Neurosurg Sci"},{"key":"4156_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1227\/01.neu.0000440729.59133.c9","volume":"55","author":"J Gault","year":"2004","unstructured":"Gault J, Sarin H, Awadallah NA, Shenkar R, Awad IA (2004) Pathobiology of human cerebrovascular malformations: basic mechanisms and clinical relevance. Neurosurgery 55:1\u201316 discussion 16\u201317","journal-title":"Neurosurgery"},{"key":"4156_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/neuros\/nyx091","volume":"80","author":"A Akers","year":"2017","unstructured":"Akers A, Al-Shahi Salman R, I AA, Dahlem K, Flemming K, Hart B, Kim H, Jusue-Torres I, Kondziolka D, Lee C, Morrison L, Rigamonti D, Rebeiz T, Tournier-Lasserve E, Waggoner D, Whitehead K (2017) Synopsis of guidelines for the clinical management of cerebral cavernous malformations: consensus recommendations based on systematic literature review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 80:665\u2013680. https:\/\/doi.org\/10.1093\/neuros\/nyx091","journal-title":"Neurosurgery"},{"key":"4156_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/bs.podrm.2017.02.006","volume":"42","author":"AA Al-Majed","year":"2017","unstructured":"Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Alajmi FM, AlRabiah H (2017) Propranolol. Profiles Drug Subst Excip Relat Methodol 42:287\u2013338. https:\/\/doi.org\/10.1016\/bs.podrm.2017.02.006","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"4156_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Foelster-Holst R, Febrer Bosch MI, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, Bernabeu-Wittel J, Valencia AM, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini AJ, Vabres P, Souteyrand P, Frieden IJ, Berul CI, Mehta CR, Prey S, Boralevi F, Morgan CC, Heritier S, Delarue A, Voisard JJ (2015) A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 372:735\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1404710","journal-title":"N Engl J Med"},{"key":"4156_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/jci144893","author":"W Li","year":"2021","unstructured":"Li W, Shenkar R, Detter MR, Moore T, Benavides C, Lightle R, Girard R, Hobson N, Cao Y, Li Y, Griffin E, Gallione C, Zabramski JM, Ginsberg MH, Marchuk DA, Awad IA (2021) Propranolol inhibits cavernous vascular malformations by \u03b21 adrenergic receptor antagonism in animal models. J Clin Invest. https:\/\/doi.org\/10.1172\/jci144893","journal-title":"J Clin Invest"},{"key":"4156_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1161\/strokeaha.120.029676","volume":"52","author":"J Oldenburg","year":"2021","unstructured":"Oldenburg J, Malinverno M, Globisch MA, Maderna C, Corada M, Orsenigo F, Conze LL, Rorsman C, Sundell V, Arce M, Smith RO, Yau ACY, Billstr\u00f6m GH, M\u00e4gi C, Beznoussenko GV, Mironov AA, Fernando D, Daniel G, Olivari D, Fumagalli F, Lampugnani MG, Dejana E, Magnusson PU (2021) Propranolol reduces the development of lesions and rescues barrier function in cerebral cavernous malformations: a preclinical study. Stroke 52:1418\u20131427. https:\/\/doi.org\/10.1161\/strokeaha.120.029676","journal-title":"Stroke"},{"key":"4156_CR9","doi-asserted-by":"publisher","DOI":"10.1159\/000519856","author":"OE Gilbert","year":"2021","unstructured":"Gilbert OE, Wilson JM, Volk JM (2021) Giant frontotemporal cavernous malformation in a 2-month-old infant: a case report and review of the literature. Pediatr Neurosurg. https:\/\/doi.org\/10.1159\/000519856","journal-title":"Pediatr Neurosurg"},{"key":"4156_CR10","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00381-020-04588-5","volume":"36","author":"JE Hoffman","year":"2020","unstructured":"Hoffman JE, Ryan M, Wittenberg B, Armstrong J, Greenan K, Wilkinson C (2020) Successful treatment of hemorrhagic brainstem cavernous malformation with hematoma evacuation and postoperative propranolol. Childs Nerv Syst 36:2109\u20132112. https:\/\/doi.org\/10.1007\/s00381-020-04588-5","journal-title":"Childs Nerv Syst"},{"key":"4156_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00381-022-05603-7","volume":"39","author":"J Tiefenbach","year":"2023","unstructured":"Tiefenbach J, Park JJ, Kaliaperumal C (2023) A 5-year outcome of propranolol for the treatment of paediatric intracranial cavernoma: case report and a review of the literature. Childs Nerv Syst 39:269\u2013272. https:\/\/doi.org\/10.1007\/s00381-022-05603-7","journal-title":"Childs Nerv Syst"},{"key":"4156_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jns.2016.04.053","volume":"367","author":"M Reinhard","year":"2016","unstructured":"Reinhard M, Schuchardt F, Meckel S, Heinz J, Felbor U, Sure U, Geisen U (2016) Propranolol stops progressive multiple cerebral cavernoma in an adult patient. J Neurol Sci 367:15\u201317. https:\/\/doi.org\/10.1016\/j.jns.2016.04.053","journal-title":"J Neurol Sci"},{"key":"4156_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.wneu.2015.11.003","volume":"88","author":"JM Zabramski","year":"2016","unstructured":"Zabramski JM, Kalani MYS, Filippidis AS, Spetzler RF (2016) Propranolol treatment of cavernous malformations with symptomatic hemorrhage. World Neurosurg 88:631\u2013639. https:\/\/doi.org\/10.1016\/j.wneu.2015.11.003","journal-title":"World Neurosurg"},{"key":"4156_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4156_CR15","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1161\/strokeaha.108.515544","volume":"39","author":"R Al-Shahi Salman","year":"2008","unstructured":"Al-Shahi Salman R, Berg MJ, Morrison L, Awad IA (2008) Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board. Stroke 39:3222\u20133230. https:\/\/doi.org\/10.1161\/strokeaha.108.515544","journal-title":"Stroke"},{"key":"4156_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"4156_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(22)00409-4","volume":"22","author":"S Lanfranconi","year":"2023","unstructured":"Lanfranconi S, Scola E, Meessen J, Pallini R, Bertani GA, Al-Shahi Salman R, Dejana E, Latini R (2023) Safety and efficacy of propranolol for treatment of Familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. Lancet Neurol 22:35\u201344. https:\/\/doi.org\/10.1016\/S1474-4422(22)00409-4","journal-title":"Lancet Neurol"},{"key":"4156_CR18","doi-asserted-by":"publisher","first-page":"E678","DOI":"10.1016\/j.wneu.2022.03.101","volume":"163","author":"L Previch","year":"2022","unstructured":"Previch L, Lanzino G, Brown RD, Flemming KD (2022) The influence of select medications on prospective hemorrhage risk in patients with spinal or cerebral cavernous malformations. World Neurosurg 163:E678\u2013E683. https:\/\/doi.org\/10.1016\/j.wneu.2022.03.101","journal-title":"World Neurosurg"},{"key":"4156_CR19","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1161\/strokeaha.121.037009","volume":"53","author":"SM Zuurbier","year":"2022","unstructured":"Zuurbier SM, Hickman CR, Rinkel LA, Berg R, Sure U, Salman R-S, Scottish Audit Intracranial Vasc M (2022) Association between beta-blocker or statin drug use and the risk of hemorrhage from cerebral cavernous malformations. Stroke 53:2521\u20132527. https:\/\/doi.org\/10.1161\/strokeaha.121.037009","journal-title":"Stroke"},{"key":"4156_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.12.035","author":"S Gomez-Paz","year":"2020","unstructured":"Gomez-Paz S, Maragkos GA, Salem MM, Ascanio LC, Lee M, Enriquez-Marulanda A, Orrego-Gonzalez E, Kicielinski K, Moore JM, Ogilvy CS, Thomas AJ (2020) Symptomatic hemorrhage from cerebral cavernous malformations: evidence from a cohort study. World Neurosurg. https:\/\/doi.org\/10.1016\/j.wneu.2019.12.035","journal-title":"World Neurosurg"},{"key":"4156_CR21","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3171\/2017.12.Jns172404","volume":"130","author":"J Goldberg","year":"2019","unstructured":"Goldberg J, Jaeggi C, Schoeni D, Mordasini P, Raabe A, Bervini D (2019) Bleeding risk of cerebral cavernous malformations in patients on beta-blocker medication: a cohort study. J Neurosurg 130:1931\u20131936. https:\/\/doi.org\/10.3171\/2017.12.Jns172404","journal-title":"J Neurosurg"},{"key":"4156_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3171\/2011.8.Jns101241","volume":"116","author":"DD Cavalcanti","year":"2012","unstructured":"Cavalcanti DD, Kalani MY, Martirosyan NL, Eales J, Spetzler RF, Preul MC (2012) Cerebral cavernous malformations: from genes to proteins to disease. J Neurosurg 116:122\u2013132. https:\/\/doi.org\/10.3171\/2011.8.Jns101241","journal-title":"J Neurosurg"},{"key":"4156_CR23","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/j.1742-4658.2009.07535.x","volume":"277","author":"F Riant","year":"2010","unstructured":"Riant F, Bergametti F, Ayrignac X, Boulday G, Tournier-Lasserve E (2010) Recent insights into cerebral cavernous malformations: the molecular genetics of CCM. FEBS J 277:1070\u20131075. https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07535.x","journal-title":"FEBS J"},{"key":"4156_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.biocel.2016.09.011","volume":"81","author":"SF Retta","year":"2016","unstructured":"Retta SF, Glading AJ (2016) Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: two sides of the same coin. Int J Biochem Cell Biol 81:254\u2013270. https:\/\/doi.org\/10.1016\/j.biocel.2016.09.011","journal-title":"Int J Biochem Cell Biol"},{"key":"4156_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.vph.2010.08.002","volume":"53","author":"S Lamy","year":"2010","unstructured":"Lamy S, Lachambre MP, Lord-Dufour S, B\u00e9liveau R (2010) Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 53:200\u2013208. https:\/\/doi.org\/10.1016\/j.vph.2010.08.002","journal-title":"Vascul Pharmacol"},{"key":"4156_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1167\/iovs.16-20204","volume":"58","author":"JA Lavine","year":"2017","unstructured":"Lavine JA, Farnoodian M, Wang S, Darjatmoko SR, Wright LS, Gamm DM, Ip MS, Sorenson CM, Sheibani N (2017) \u03b22-adrenergic receptor antagonism attenuates CNV through inhibition of VEGF and IL-6 expression. Invest Ophthalmol Vis Sci 58:299\u2013308. https:\/\/doi.org\/10.1167\/iovs.16-20204","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4156_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.phrs.2009.05.005","volume":"60","author":"B Annabi","year":"2009","unstructured":"Annabi B, Lachambre MP, Plouffe K, Moumdjian R, B\u00e9liveau R (2009) Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60:438\u2013445. https:\/\/doi.org\/10.1016\/j.phrs.2009.05.005","journal-title":"Pharmacol Res"},{"key":"4156_CR28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1097\/PRS.0b013e318267d3db","volume":"130","author":"A Wong","year":"2012","unstructured":"Wong A, Hardy KL, Kitajewski AM, Shawber CJ, Kitajewski JK, Wu JK (2012) Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. Plast Reconstr Surg 130:1012\u20131021. https:\/\/doi.org\/10.1097\/PRS.0b013e318267d3db","journal-title":"Plast Reconstr Surg"},{"key":"4156_CR29","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.jpedsurg.2012.09.008","volume":"47","author":"Y Ji","year":"2012","unstructured":"Ji Y, Li K, Xiao X, Zheng S, Xu T, Chen S (2012) Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg 47:2216\u20132223. https:\/\/doi.org\/10.1016\/j.jpedsurg.2012.09.008","journal-title":"J Pediatr Surg"},{"key":"4156_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1489657","volume":"15","author":"S Dryga\u0142a","year":"2024","unstructured":"Dryga\u0142a S, Radzikowski M, Maciejczyk M (2024) \u03b2-blockers and metabolic modulation: unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress. Front Pharmacol 15:1489657. https:\/\/doi.org\/10.3389\/fphar.2024.1489657","journal-title":"Front Pharmacol"},{"key":"4156_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/bf00543705","volume":"28","author":"JM Cruickshank","year":"1985","unstructured":"Cruickshank JM, Neil-Dwyer G (1985) Beta-blocker brain concentrations in man. Eur J Clin Pharmacol 28:21\u201323. https:\/\/doi.org\/10.1007\/bf00543705","journal-title":"Eur J Clin Pharmacol"},{"key":"4156_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/ANA.0b013e318232deaa","volume":"24","author":"A Zlotnik","year":"2012","unstructured":"Zlotnik A, Klin Y, Gruenbaum BF, Gruenbaum SE, Ohayon S, Leibowitz A, Kotz R, Dubilet M, Boyko M, Shapira Y, Teichberg VI (2012) \u03b22 adrenergic-mediated reduction of blood glutamate levels and improved neurological outcome after traumatic brain injury in rats. J Neurosurg Anesthesiol 24:30\u201338. https:\/\/doi.org\/10.1097\/ANA.0b013e318232deaa","journal-title":"J Neurosurg Anesthesiol"},{"key":"4156_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jss.2015.08.020","volume":"200","author":"B Zangbar","year":"2016","unstructured":"Zangbar B, Khalil M, Rhee P, Joseph B, Kulvatunyou N, Tang A, Friese RS, O\u2019Keeffe T (2016) Metoprolol improves survival in severe traumatic brain injury independent of heart rate control. J Surg Res 200:586\u2013592. https:\/\/doi.org\/10.1016\/j.jss.2015.08.020","journal-title":"J Surg Res"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04156-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:04:59Z","timestamp":1770653099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04156-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4156"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04156-6","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}